Suppr超能文献

沉默调节蛋白7的缺失会损害细胞的运动性和增殖能力,并增强头颈部癌在接受5-氟尿嘧啶治疗后的S期细胞阻滞。

Loss of Sirtuin 7 impairs cell motility and proliferation and enhances S-phase cell arrest after 5-fluorouracil treatment in head and neck cancer.

作者信息

Halasa Marta, Afshan Syeda, Wawruszak Anna, Borkowska Agata, Brodaczewska Klaudia, Przybyszewska-Podstawka Alicja, Kalafut Joanna, Baran Marzena, Rivero-Müller Adolfo, Stepulak Andrzej, Nees Matthias

机构信息

Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, 20-093, Poland.

FICAN West Cancer Centre, Institute of Biomedicine, University of Turku, Turku, 20520, Finland.

出版信息

Sci Rep. 2025 Jan 16;15(1):2123. doi: 10.1038/s41598-024-83349-9.

Abstract

Sirtuin 7 (SIRT7), a member of the sirtuin family of NAD+-dependent deacetylases, plays a vital role in cancer, exhibiting context-dependent functions across various malignancies. Our study investigates the role of SIRT7 depletion in head and neck squamous cell carcinoma (HNSCC) progression. In vitro and 3D organotypic models demonstrated that SIRT7 knock-out attenuates cancer cell viability, proliferation, and motility as well as induces downregulation of migration- and epithelial-mesenchymal transition (EMT)-related gene expression. Moreover, the SIRT7 loss results in slower organoid formation and less invasive organoid morphology, validated by vimentin downregulation. The SIRT7 loss potentiates S-phase arrest in cell cycle progression after 5-FU treatment and elevates the ratio of dead cells. Additionally, SIRT7 deletion reduces the expression of G1 phase-associated proteins, Cyclin D and CDK4. Altogether, our study highlights SIRT7 as a promising therapeutic target in HNSCC, enhancing the effectiveness of treatment modalities such as combinational treatment.

摘要

沉默调节蛋白7(SIRT7)是烟酰胺腺嘌呤二核苷酸(NAD+)依赖性去乙酰化酶沉默调节蛋白家族的成员,在癌症中发挥着至关重要的作用,在各种恶性肿瘤中表现出依赖于环境的功能。我们的研究调查了SIRT7缺失在头颈部鳞状细胞癌(HNSCC)进展中的作用。体外和三维器官型模型表明,SIRT7基因敲除会减弱癌细胞的活力、增殖和迁移能力,并诱导与迁移和上皮-间质转化(EMT)相关的基因表达下调。此外,SIRT7缺失导致类器官形成更慢,类器官形态侵袭性更小,波形蛋白下调验证了这一点。SIRT7缺失增强了5-氟尿嘧啶(5-FU)处理后细胞周期进程中的S期阻滞,并提高了死细胞比例。此外,SIRT7缺失会降低G1期相关蛋白细胞周期蛋白D(Cyclin D)和细胞周期蛋白依赖性激酶4(CDK4)的表达。总之,我们的研究突出了SIRT7作为HNSCC中有前景的治疗靶点,可提高联合治疗等治疗方式的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a10b/11739472/a3e8bf32d4c1/41598_2024_83349_Figa_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验